Results from the SOUL Trial: The Diabetologists' Perspective

Watch the full interview on YouTube to learn more about the SOUL trial, a landmark study presented at the EASD 2025 Annual Meeting investigating cardiovascular outcomes with an oral GLP-1 receptor agonist.

In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains why the SOUL trial represents a significant milestone in diabetes and cardiovascular care. She discusses how the oral formulation achieved a 14% reduction in major adverse cardiovascular events (MACE), matching results previously observed with injectable GLP-1 therapies.

Dr Busui also explores:

• The relevance of the findings for people with type 2 diabetes at high cardiovascular risk
• New insights into heart failure phenotypes, particularly HFpEF, and their growing prevalence
• Why oral GLP-1 therapies may help expand access, especially for older adults or those unable to manage injections
• Key safety observations regarding combined use with SGLT2 inhibitors, which was seen in nearly half of trial participants

Read the full publication for a deeper dive into the SOUL trial data once available online.

Stay tuned for more expert insights and breakthrough conversations from EASD TV. To learn more about our expert speaker:

• Dr Rodica Busui